Maastricht-based PathoFinder Rijksoverheid approved Covid-19 test kit provider
Updated: Jan 7, 2021
PathoFinder and EWC Diagnostics partnership to meet COVID-19 testing demands in the Netherlands.
PathoFinder and EWC Diagnostics announce their collaboration to rapidly advance the expansion of COVID-19 testing capacity in the Netherlands by providing Rijksoverheid with complete sets of sampling materials and SARS-CoV-2 PCR kits.
Within this strategic partnership, EWC provides nasal- and throat swabs and Viral Transport Medium (VTM). PathoFinder produces the RealAccurate Quadruplex SARS-CoV-2 PCR kit (CE-IVD), which has been validated and approved by the Rijksinstituut voor Volksgezondheid en Milieu – RIVM. The PCR kit targets both the N gene and the RdRp gene of the virus, allowing viral detection as well as confirmation of a positive result, in one. EWC Diagnostics coordinates and distributes this unique combination of products to all test locations in the Netherlands.
EWC Diagnostics, based in Steenwijk, the Netherlands, delivers a wide range of products and services to microbiological laboratories in the Benelux. From the start of the COVID-19 pandemic, EWC accelerated their support and distribution of COVID-19 testing materials to Dutch hospitals, and have proven to be a reliable partner for the government.
The molecular diagnostics firm PathoFinder, based in #Maastricht in the Netherlands, develops and commercializes multiplex in-vitro diagnostics for infectious diseases. PathoFinder is particularly active in the fields of respiratory tract infections, meningitis and encephalitis, gastro-intestinal infections and sexually transmitted diseases. PathoFinder have developed and launched four SARS-CoV-2 kits since March 2020 and continue to grow and meet the increased demand for COVID-19 testing.
This collaboration of Dutch SME’s brings molecular diagnostics expertise together to better meet the vast testing capacity demands created by the SARS-CoV-2 pandemic.
Photo: © PathoFinder and EWC Diagnostics 2020